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Invasive lobular carcinoma (ILC) accounts for approximately 10% of invasive breast 
carcinoma and its incidence appears to be increasing especially amongst post-
menopausal women. Morphologically, ILC is characterised by cells that are bland in 
appearance, have scant cytoplasm and infiltrate the stroma in single files. Probably due 
to its diffuse infiltrative growth pattern, ILC tends to be less discrete when presenting as 
a breast lump. Radiological studies in early diagnosis can be challenging as it tends to 
permeate imperceptibly through the breast stroma, thus leading to often occult 
mammographic appearances. 
 
ILC is the second most common histologic type of breast cancer and its incidence is 
reported to be lower in Asian countries compared to the western population. Studies on 
the clinical outcome and prognostic characteristics of ILC have been few in the Asian 
population, therefore, warranting a detailed study of their clinical features and outcome 
in the Singapore population. In this study, the clinicopathological characteristics and 
immunohistochemical profile of ILC in a large series of Singaporean women were 
assessed, including its association with triple negativity and basal phenotype. Using 
immuno-markers Estrogen Receptor (ER), Progesterone Receptor (PR), HER-2, 
Mammaglobin, Ki-67, Cytokeratin High Molecular Weight (CK HMW), Cytokeratin 14 
(CK14) and Epidermal Growth Factor Receptor (EGFR), this study investigated the 




carcinoma (IDC), the pleomorphic and non-pleomorphic variants of ILC, triple negative 
ILC and non-triple negative ILC and lastly between basal-like ILC and non basal-like ILC.  
 
In these analyses, mixed ILC/IDC was associated with higher histologic grade, tubulo-
lobular variant, absence of associated lobular carcinoma in-situ and HER-2 positivity. 
Pleomorphic variant was associated with higher histologic grade, increased proliferative 
activity, positive EGFR status, negative ER and PR status. Triple negativity was associated 
with older age, higher histologic grade, the pleomorphic variant, negativity for CK HMW 
and Mammaglobin. Basal phenotype was defined as expression of at least one of the 
two immuno-markers CK14 or EGFR. This phenotype was associated with older age and 
presence of accompanying LCIS. Molecular classification using surrogate 
immunohistochemical markers ER, PR and HER-2 revealed the HER-2 overexpressing 
molecular subtype to have the worst disease -free outcome. 
 
Similar to other Asian countries, incidence of ILC is relatively low in Singapore. The 
pleomorphic variant, triple negativity and the basal phenotype in ILC were associated 
with worse characteristics but have no impact with regard to patient survival. Some of 
the clinicopathological parameters have been re-emphasized to predict patient outcome 
and in this study, tumour size, histologic grade and lymph node status remained as 
important independent prognostic indicators. The biology and outcome of ILC between 
the Asian and Western populations were very similar and this study found no grounds 
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1.1 Breast anatomy 
 
The female breast rests largely on the pectoralis major muscle and lymph nodes are 
located around the breast edges or in nearby tissues of the armpits and collarbone. The 
mature adult breast contains 15–20 grossly defined lobes. Each lobe, with its 
corresponding parenchyma, is associated with a major lactiferous duct that terminates 
in the nipple. At the end of the terminal ducts are lobules which produce milk. The 
glandular and ductal components of the breast are embedded in tissue which consist of 
adipose tissue (fats) and collagenous stroma. This fibro-fatty matrix holds and shapes 
the breast.  
 
At puberty, estrogen stimulates the growth of ducts and thickening of epithelium and 
periductal stroma. Growth hormone and glucocorticoids contribute to ductal growth. 
Lobuloalveolar differentiation and growth during this period are enhanced primarily by 
insulin, progesterone, and growth hormone (Topper and Freeman 1980).  
 
Lymph nodes play a vital role in the spread of breast cancer. The axillary lymph nodes 
are particularly important, as they receive more than 75 % of the lymphatic flow 
(Estourgie et al. 2004). Axillary lymph nodes are likely the first places that metastatic 





staging and prognosis of cancer as well as prevention of axillary recurrence (Black et al. 
1953).  
 
Cancer cells arise from epithelial cells of the terminal duct lobular unit or the ducts. 
They divide uncontrollably to break through the basement membrane and are no longer 
confined to the lumens of the ducts or lobules (Barsky et al. 1983). 
 
1.2 Classification of breast cancer 
 
The latest World Health Organization (WHO) classification of breast cancer recognises 
the existence of 18 histologic types of breast cancer and their variants according to 
Table 1.2.1 (Tavassoli and Devilee 2003). This classification includes Invasive Ductal 
Carcinoma- No Special Type (IDC-NST) and 17 special types. IDC-NST accounts for the 
majority of all breast carcinomas and it makes up approximately 50-80% of all diagnosed 
breast cancers. ILC accounts for 5-20% of all invasive breast cancers and it is the most 







Table 1.2.1 WHO classification of breast cancer. 
WHO classification of breast cancer (2003) 
 
Epithelial tumours 
1 Invasive ductal carcinomas of no special type 
 • Mixed type carcinoma 
 • Pleomorphic carcinoma 
 • Carcinoma with osteoclastic giant cells 
 • Carcinoma with choriocarcinomatous features 
 • Carcinoma with melanotic features 
2 Invasive lobular carcinomas 
 • Classical lobular carcinoma 
 • Alveolar lobular carcinoma 
 • Solid lobular carcinoma 
 • Pleomorphic lobular carcinoma 
 • Tubulolobular carcinoma 
3 Mucinous carcinomas 
 • Mucinous carcinoma 
 • Cystadenocarcinoma 
 • Signet ring cell carcinoma 
4 Medullary carcinoma  
5 Invasive papillary carcinoma 
6 Invasive cribriform carcinoma 
7 Metaplastic carcinomas 
 • Pure epithelial metaplastic carcinomas  
  →Squamous cell carcinomas 
  →Adenocarcinoma with spindle cell metaplasia  
  →Adenosquamous carcinoma 
  →Mucoepidermoid carcinoma  
 • Mixed epithelial/mesenchymal metaplastic carcinomas  
8 Tubular carcinoma 
9 Adenoid cystic carcinoma 
10 Secretory carcinoma 
11 Apocrine carcinoma 
12 Neuroendocrine tumours 
 • Solid neuroendocrine carcinoma 
 • Atypical carcinoid tumour  
 • Small cell / oat cell carcinoma  
 • Large cell neuroendocrine carcinoma  
13 Glycogen-rich clear cell carcinoma 
14 Lipid-rich clear cell carcinoma 
15 Invasive micropapillary carcinoma 
16 Acinic cell carcinoma 
17 Oncocytic carcinoma 





1.3 Breast cancer statistics: Global and local 
 
1.3.1 Breast cancer statistics (all types breast cancer) 
 
Breast cancer is the most frequently diagnosed cancer in women and is the leading 
cause of cancer death amongst women worldwide (Table 1.3.1)(Garcia et al. 2007). 
Although breast cancer incidence is on the rise worldwide, mortality rate from this 
disease has been stable or decreasing in some countries as a result of early detection 
and improved treatment (Garcia et al. 2007).  
 
In Singapore, breast cancer is the most frequently diagnosed cancer in females (Figure 
1.3.1). Over the last 4 decades, since the Singapore Cancer Registry started collecting 
and reporting statistics on cancer, breast cancer incidence has been increasing (Figure 





Table 1.3.1 Leading cancer sites of new cases and deaths worldwide.  
Estimated numbers were taken from Global cancer facts & figures 2007 (Garcia et al. 
2007). 
Worldwide (Female) 
  Estimated new cases Estimated deaths 
     
1 Breast Breast 
  1,301,867 464,854 
     
2 Cervix uteri Lung & bronchus 
  555,094 376,410 
     
3 Colon & rectum Cervix uteri 
  536,662 309,808 
     
4 Lung & bronchus Stomach 






Figure 1.3.1 Ten most frequent cancer sites in Singaporean women. 
Taken from Trends in cancer incidence in Singapore 2003-2007 with permission from 








Figure 1.3.2 Incidence of breast cancer in Singaporean female from 1968 to 2007. 
Taken from Trends in cancer incidence in Singapore 2003-2007 with permission from 
National Registry of Diseases Office. 
 
 
Table 1.3.2 Leading cancer sites of deaths in Singapore females from 2003-2007. 
Taken from Trends in cancer incidence in Singapore 2003-2007 with permission from 







1.3.2  Breast cancer statistics on ILC 
 
Incidence of ILC ranges as low as 1-4% to as high as 5-10% in different regions and 
dependent on how restrictive the diagnostic criteria are. Among the Asian countries, 
Korea reported its incidence as 2.8% from 2001 to 2008 (Jung et al. 2010) and a 
Japanese clinical study consisting of 549 cases over 16 years found their incidence to be 
1.3% (Tanaka et al. 1987). The breast centre at the Baylor College of Medicine reported 
8.2% of breast cancer diagnosed as ILC between 1970 and 1998 (Arpino et al. 2004). A 
meta-analysis of 15 Internal Breast Cancer Group trials between 1978 and 2002, 
totalling 1,206 subjects, had 6.2% of breast cancer classified as ILC (Pestalozzi et al. 
2008).  
 
In Singapore, the incidence of ILC was on the low end of the range. From 2003-2007, ILC 
comprised 3.9% of all breast cancers (Singapore Cancer Registry 2009). From 1994-2008, 
the proportion of pure ILC diagnosed is 6.3% and 2.3% for mixed ILC/IDC in the 
department of Pathology, Singapore General Hospital (SGH). 
 
Table 1.3.3 Proportion of ILC diagnosed in different countries. 
Country                                Proportion of ILC Year  Source  
Korea  2.8% 2001-2008  Jung et al., 2010 
Japan  1.3% Last 16 years  Tanaka et al., 1987  
USA (Baylor College of Medicine)  8.2% 1970-1998  Arpino et al., 2004  
USA 7.6% 1987-1999 Christopher I. Li, 2003 
Switzerland 6.8% 1976-1999 Verkooijen et al., 2003  
International (Meta-analysis)  6.2% 1978-2002  Pestalozzi et al., 2008 
Singapore (National) 3.9% 2003-2007 Singapore Cancer Registry  





1.4 Background on Invasive Lobular Carcinoma (ILC) of the breast 
 
Invasive lobular carcinoma (ILC) of the breast was first fully described and established in 
1941 (Foote and Stewart 1941). The in-situ components were described as having 
uniform cells with non-hyperchromatic nuclei and disorderly arrangement, loosely 
displaced towards the lumen of the terminal ducts. Their invasive counterparts were 
described as uniformly sized cells, disorientated arrangement in a circumferential 
manner around ducts and lobules (targetoid growth) (Figure 1.4.1). Foote and Stewart 
believed that these cells were indicative of malignancy and had to be radically treated 
(Foote and Stewart 1941). Their criteria for reporting of ILC have been widely accepted, 




Figure 1.4.1 (A) Benign lobules (B) Classic ILC characterised by monomorphic cells that 






ILC has clinicopathological characteristics that are different from invasive ductal 
carcinoma (IDC). Large population-based studies seen the incidence of IDC kept 
relatively constant while the incidence of ILC and mixed ILC/IDC have increased over the 
years (Verkooijen et al. 2003;Li et al. 2003).  ILC is often more difficult to detect at an 
earlier stage due to its reduced tendency to form palpable masses. This may be 
attributed to its linear pattern of infiltration eliciting little desmoplastic stromal 
response. There are contradicting findings on prognosis of ILC, with many studies 
reporting better outcome compared to IDC (Korhonen et al. 2004;Arpino et al. 2004), 
while a study with long term follow-up reported the contrary (Pestalozzi et al. 2008). 
 
1.5 Histologic variants of ILC 
 
The definition of ILC was broadened to include other growth patterns of ILC. In these 
variants, tumour cells have similar cytologic characteristics as the classical variant but 
lacks the linear growth pattern (Fechner 1975;Shousha et al. 1986;Fisher et al. 
1977;Eusebi et al. 1992;Buchanan et al. 2008). Several variants had been described 
including alveolar, solid, tubulo-lobular and pleomorphic variants. The pleomorphic 
variant, in particular, has been shown to be associated with more aggressive clinical 
behaviour and worse clinical outcome. A study comparing pleomorphic lobular 
carcinoma with classic ILC and IDC demonstrated that the pleomorphic variant tended 
to present at a more advanced stage with larger tumour size and more lymph node 





consistently shown to have less favourable outcome when compared to patients 
harbouring tumours of the classic ILC variant (Weidner and Semple 1992;Arpino et al. 
2004) .  
 
1.6 Clinical features of ILC 
 
ILC are often diagnosed in older patients compared to IDC (Pestalozzi et al. 2008;Sastre-
Garau et al. 1996;Albrektsen et al. 2010). In a Norwegian study of association of 
histologic types with reproductive trend, proportion of IDC remained constant across 
age groups while proportion of ILC increased markedly with increasing age (Karl N. 
Krecke 1983).  
 
Radiological studies in early diagnosis of ILC can be challenging as it tends to permeate 
imperceptibly through the breast stroma. It is less likely to be associated with 
calcification and its low opacity may contribute to more difficulty in detecting ILC 
(Yeatman et al. 1995), hence a basis for its underestimation on mammography 
compared to IDC (Chen et al. 2002). ILC have been reported to be bigger tumours 
compared to IDC, with increasing number of metastatic lymph nodes associated with 
tumour size (Yeatman et al. 1995). It has also been shown to be associated with 






ILC have been reported to have higher incidence of positive margin after breast 
conservation surgery (Santiago et al. 2005). Breast conserving surgery on ILC can be 
challenging as it is often associated with more false-negative margins resulting in a 
higher frequency of conversion to mastectomy subsequently (Moore et al. 2000). Yet, 
comparing breast conservation surgery for early stage ILC and IDC, there seems to be no 
significant difference in 10 year overall survival, recurrence and disease-free status. 
There is also no difference in risk of developing contralateral breast carcinoma (Peiro et 
al. 2000;Kelsey et al. 1993). 
 
1.7 Risk Factors of ILC 
 
Being female without a doubt puts one at risk of developing breast cancer. Well-
established familial mutations such as BRCA1 and BRCA2 mutations are widely-known 
inheritable susceptibility genes for breast cancer. High breast tissue density (a 
mammographic measure of the amount of glandular tissue relative to fatty tissue in the 
breast) is associated with higher breast cancer risk. Biopsy confirmed hyperplasia of 
breast tissue especially atypical hyperplasia, and high-dose radiation to the chest as a 
result of medical procedures are also risk factors. Epidemiologic studies have shown 
that reproductive and lifestyle exposures are predictive of subsequent breast cancer risk. 
Non-modifiable long-established reproductive risk factors include a long menstrual 
history (early age at menarche and late menopause), nulliparity, recent use of oral 





Other behavioural and lifestyle risk factors, particularly relevant after menopause, 
include physical inactivity, menopausal hormone therapy use, alcohol consumption, and 
high body mass index (Biglia et al. 2007). 
 
Whereas the incidence of IDC has remained stable, the incidence of ILC appears to be 
increasing especially amongst post-menopausal women. Recent studies have suggested 
the association of use of hormone replacement therapy with this trend (Tanaka et al. 
1987;Newcomb et al. 2010). Older age at first full term pregnancy and older age at 
menarche are significantly associated with elevated risk of ILC. This risk is statistically 
different for ILC and IDC (Albrektsen et al. 2010;Li et al. 2006). Alcohol use has a more 
pronounced increased risk of developing lobular carcinoma, especially among 
postmenopausal women. This risk again differs between lobular and ductal tumours 
(Stange et al. 2006). 
 
1.8 Molecular pathology of ILC 
 
Breast cancer is a heterogeneous disease that arises from accumulation of complex 
array of genomic alterations. Many studies have attempted to characterise these 
genomic alterations and make sensible relationship to clinical behaviour and 
morphology. Recent genetic profiling studies have revealed unique changes in ILC at the 
molecular level. Comparative genomic hybridisation (CGH) is a technique that allows 





frequently employed to characterise breast cancer. Commonly reported DNA copy 
number changes unique to ILC include gain of 1q and 5p, and loss of 16q, 16p, 17p, 
18q12–q21, and 22q. (Loveday et al. 2000;Günther et al. 2001;Zhao et al. 2004)  
 
Genome-wide expression profiling techniques have identified abnormal gene 
regulations in ILC. Downregulation of E-cadherin reflects results of CGH analysis where 
loss of genetic material in the region of 16q chromosome corresponds to CDH1 gene 
resulting in its low transcription and expression.  Genes related to basal epithelial cell 
markers (e.g., KRT 5, KRT 17, and EGFR) are also identified to be downregulated in ILC 
(Weigelt et al. 2010). Other differential expressions include downregulation of genes 
involved in DNA repair, proliferation/cell cycle activities and up-regulation of genes 
involved in lipid/prostaglandin biosysnthesis and cell migration (Simpson et al. 2008). 
  
Pleomorphic ILC was shown to be more similar to ILC than IDC at the genomic level. 
Further accumulation of genomic abnormality is associated with the pleomorphic 
variant and this may explain the aggressive nature of ILC. Loss of BRCA2 is reported at a 
higher proportion in pleomorphic ILC (Berx et al. 1996). 
 
1.9 E-cadherin and p120 catenin 
 
E-cadherins are a class of transmembrane proteins and they are involved in cell to cell 





lobular cancer cells and cancer progression by increasing proliferation, invasion and 
metastasis. Negative E-cadherin expression is one of the major defining features of 
lobular tumours; rather than a prognostic factor to differentiate between the outcomes 
of ductal and lobular tumours (Coradini et al. 2002). Lobular carcinomas have 
diminished, absent or aberrant E-cadherin expression, while presence of complete 
membrane staining indicates ductal phenotype. 
 
p120 catenin belongs to a group of proteins called catenins and it is attached to the 
juxtamembrane domain of E-cadherin in the intracellular cytoplasm. p120 catenin’s  
expression in the cell membrane is an indication that E-cadherin is intact in the cell 
membrane, while its localisation to the cytoplasm suggests E-cadherin is non-functional 
or absent. Cytoplasmic localisation of p120 catenin is a positive marker for lobular 
neoplasia, from the early stage of atypical lobular hyperplasia to invasive lobular 
carcinoma (Sarrió et al. 2004). It has been reported to be helpful in diagnosis of 
metastatic lobular carcinoma (Dabbs et al. 2007). A positive p120 marker may be easier 
to interpret in some instances compared to negative E-cadherin expression, especially 
when E-cadherin is also expressed in myoepithelial cell membranes, hence presenting a 







Figure 1.9.1 Expression of E-cadherin in normal ducts and in ILC. 
(A) Presence of complete E-cadherin membrane staining in normal ductal component 




1.10 Scope of study 
 
Studies on the clinical outcome and prognostically significant characteristics of ILC have 
been few in the Asian population. This warrants a detailed study of their 
clinicopathological features and outcome in the Singapore population including their 
association with triple negativity and basal phenotype. I propose to document more 
comprehensively the clinicopathological characteristics and immunohistochemical 




The lobular histologic subtypes of breast cancer, although similar in many histological 






that exhibit basal-like characteristics and the pleomorphic morphology of tumour cells 
are predictors that are associated with poor patient outcome. This current work 
hypothesizes that a subset of lobular cancers which exhibit these characteristics will 
have worse outcome. 
 
The objectives of this study are as follows: 
 
1. To establish prognostic and predictive values of clinicopathological characteristics 
and immuo-markers in ILC. The immuno-markers to be assessed are ER, PR,  
HER-2, Mammaglobin, Ki-67, CK HMW, CK14 and EGFR. 
2. To investigate the differences in characteristics and outcome of ILC and mixed 
ILC/IDC. 
3. To determine the significance of the pleomorphic variant of ILC. 
4. To evaluate the existence and significance of triple negativity in ILC. 
5. To ascertain the existence and significance of basal phenotype in ILC. 
6. To determine the significance of molecular subtyping using surrogate markers ER, PR 
and HER-2 
7. To survey the usefulness of E-cadherin and p120 expression in interpretation of ILC 
by documenting the frequency of aberrant E-cadherin staining pattern, p120 catenin 
cytoplasmic expression and determine the association of E-cadherin expression 
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2 Materials and Methods 
 
2.1 Study Population 
 
The study population was derived from the database in the archives of the Pathology 
Department of Singapore General Hospital (SGH). All patients with invasive lobular 
carcinoma of the breast diagnosed at the Pathology Department (SGH) were identified. 
A total of 669 cases, including pure ILC and mixed ILC/IDC histologic types were reported. 
Patients who did not have archival materials available in the department were excluded 
from the study. Haematoxylin and Eosin (H&E) stain and E-cadherin 
immunohistochemistry were preformed on whole tumour sections. Tumours that did 
not express E-cadherin or tumours where E-cadherin expression was aberrant were 
included in the study and representative tumour areas were selected for Tissue Micro-
Array (TMA) construction. A final of 345 cases from 1994 to 2008 were used in this study. 
Centralised Institutional Review Board approval was obtained. 
 
2.2 Tissue Micro-Array (TMA) Construction 
 
In this study, representative areas of tumour were circled on H&E sections. Only tumour 
areas with a morphologically lobular appearance were chosen. In addition, E-cadherin 
stained sections of the same areas were screened to verify negativity or aberrant 
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expression for E-cadherin. 1mm core and 2 cores per case were used for TMA 
construction as illustrated in Figure 2.2.1. 
 
 
Figure 2.2.1 Schematic representation of TMA construction and resulting TMA section.  
 (A) Beecher Tissue microarrayer. (B) Tissue cores are removed from the ‘donor’ block 
and inserted into premade holes of the ‘recipient’ block. Microtomes are used to cut 
TMA sections. (C) Overview of a H&E stained TMA section. (D) Magnification of H&E 
spot and immunohistochemistry spot. 
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2.3 Patient’s Clinicopathological Characteristics  
 
Patients’ clinicopathological history and tumour characteristics including age, ethnicity, 
tumour size, histological grade, lobular variant, accompanying lobular carcinoma in-situ 
(LCIS), lymphovascular invasion (LVI) and lymph node (LN) status were obtained from 
the database. H&E tumour sections were reviewed and the tumours were classified as 




Immunohistochemistry was performed by the polymeric-based two-step method. This 
method consists of a compact polymer to which multiple molecules of enzyme (to 
catalyse substrate for visualisation) and the secondary antibody (specific for the primary 
antibody) are attached (Figure 2.4.1).  
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Immunohistochemical assays were performed on formalin-fixed paraffin embedded 
sections. Four µm thick sections were cut from the TMA blocks, mounted on silanized 
glass slides and dried on heating bench for at least 20 minutes. The sections were 
deparaffinised in 2 changes of xylene for 2 min each. This was followed by rehydration 
in decreasing concentration of alcohol from 100% followed by 95% to 75% and finally in 
water. The rehydrated slides were subjected to antigen retrieval according to Table 
2.4.1. For heat-induced antigen retrieval, slides were heated in 0.01M Tris-0.001M EDTA 
pH9 antigen retrieval solution for 15 minutes at sub-boiling temperature of 98°C in a 
microwave (Milestone T/T mega). For enzymatic antigen retrieval, sections were 
incubated with protease for 10 minutes at 40ºC. Slides were then run on Dako 
Autostainer Plus according to the following steps: Endogenous peroxidase activity was 
blocked using hydrogen peroxide (Dako S2022) for 10 minutes. Slides were incubated 
with the respective optimally diluted primary antibody for 30 minutes at room 
temperature. Detection was achieved using Dako Envision Detection kit  (Dako K5007) 
which is a dextran backbone conjugated with secondary antibodies to mouse or rabbit 
immunoglobulin and horseradish peroxidase (Figure 2.4.1). Addition of substrate 
chromogen, diaminobenzidine (DAB) for 5 minutes will produce an insoluble brown 
precipitate catalysed by HRP.  
 
Slides were removed from the autostainer and countered stained with Mayer’s 
Haematoxylin (Dako S3309) for 1 minute and coverslipped. Appropriate controls were 
run with each batch of slides.  
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Table 2.4.1 Antibody Details. 
Primary 
Antibody 





ER SP1 Rabbit 
Monoclonal 
#RM-9101-R7 1:50 TE 
PR PgR 636 Mouse 
Monoclonal 
Dako M3569 1:200 TE 
HER-2 SP3 Rabbit 
Monoclonal 
#RM-9103-R7 1:200 TE 











CK HMW 34BE12 Mouse 
Monoclonal 
Dako M0630 1:200 TE 





EGFR  E30 Mouse 
Monoclonal 
Dako M7239 1:50 Protease 
E-cadherin NCH-38 Mouse 
Monoclonal 
Dako M3612 1:30 TE 






ER, PR, Ki-67 are localised in the nucleus, CK14, CK HMW and Mammaglobin are 
localised in the cytoplasm. EGFR, HER-2 and E-cadherin have cytoplasmic membrane 
decoration. p120 catenin stains cytoplasm of lobular tumour cells while ductal cells have 
cytoplasmic membrane localisation. Scores were semi-quantitated, staining intensity of 
0, 1, 2, 3 corresponding to nil, weak, moderate and strong and the proportion of total 
number of positive tumour cells were recorded. Cut-off values for the different 
immuno-markers were chosen for statistical analysis. SGH histopathology department 
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cut-offs were used for established prognostic immuno-markers. For ER and PR status, at 
least 1% of tumour cells have to display a minimum of 1+ nuclear staining to be 
considered positive, according to the American Society of Clinical Oncology/College of 
American Pathologists (ASCO/CAP) guidelines (Hammond et al. 2010). For HER-2 
positive status, more than 30% of tumour cells have to exhibit 3+ uniform intense 
cytoplasmic membrane staining, according to the ASCO/CAP guidelines ((Wolff et al. 
2007). Ki-67 high expression was defined as ≥10% of positive tumour cells. E-cadherin 
membranous expression of at least 10% of tumour cells was considered positive for 
prognostic comparison. For the remaining immuno-markers (CK HMW, CK14, EGFR, 
mammglobin and p120 catenin), cut-off of at least 1% positive tumour cells stained 
defined positive status. 
 
2.5 Statistical analysis 
 
Associations between categorical variables and status of immuno-markers were 
assessed using Chi-square and Fisher’s exact tests. Survival data including survival time, 
disease-free interval and development of distant metastasis were retrieved from the 
database. The primary endpoints of this study were Disease-Free Survival (DFS) and 
Overall Survival (OS). DFS was defined as the length of time between date of diagnosis 
and first observation of disease recurrence, either loco-regional recurrence (including 
ipsilateral and contralateral breast recurrence) or distant metastasis censored at time of 
last follow-up or death from any cause. OS was defined as the interval between date of 
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diagnosis and death from all causes. Survival plots according to selected tumour 
characteristics and immuno-marker status were drawn using the Kaplan-Meier method. 
The log rank test was used to assess survival differences between strata. Univariate and 
multivariate Cox proportional hazards regression analyses were used to assess the 
independent prognostic significance of clinicopathological parameters and immuno-
markers on survival.  Initially, a univariate analysis was performed and parameters 
identified as significant were included in a multivariate analysis.  Parameters included in 
the analyses were age, tumour size, histologic grade, accompanying LCIS, LVI, LN status. 
Hazard ratio was presented with 95% confidence intervals. Analyses were performed 
using Statistical Package for the Social Science (SPSS), version 18. All p-values are two-











The classical variant as shown in Figure 3.1.1 has monomorphic small or medium-sized 
discohesive cells harbouring centrally positioned nuclei and exhibiting slight 
hyperchromasia. The tumour cells are arranged as monolayers in a linear fashion and 
this arrangement may be seen around ducts or lobules in a concentric pattern termed 
“targetoid” appearance.  
 
 










In the alveolar variant (Figure 3.1.2), the tumour cells have the same uniform 
appearance as the classical type. Architecturally, they are made up of alveolated clusters 
of about 20 tumour cells separated by a slender bands of stroma (Fechner 
1975;Martinez and Azzopardi 1979).  
 
 






The solid variant (Figure 3.1.3) is made up of irregularly shaped solid sheets of tumour 












In addition to cords of tumour cells growing in a linear pattern, the tubulo-lobular 
variant (Figure 3.1.4) is composed of tumour cells organised in a tubular configuration of 
smaller size, resembling tubular carcinoma (Fisher et al. 1977).  
 
 








The pleomorphic variant (Figure 3.1.5) is distinguished by tumour cells that are more 
hyperchromatic and have greater degree of nuclear contour irregularities compared to 
the classic variant. Cytoplasm can be abundant and eosinophilic and nucleoli can be 
distinct (Middleton et al. 2000;Rosen 2001). 
 
  






3.2 Patients and tumour characteristics 
 
A final number of 345 patients with pure ILC and mixed ILC/IDC were included for 
analysis. Table 3.2.1 summarised the clinical and histopathological features for the 
entire series. Out of these cases, 246 were pure ILCs and 99 were mixed ILC/IDCs. The 
age ranged from 25-86 years, mean age was 55 years. Majority of patients were Chinese 
(80.6%), Malays made up 6.7%, Indians 5.5% and other ethnicities 5.2% of the series. 
There were 5 (1.4%) cases without ethnicity records. Tumour size ranged from 1mm to 
130mm, mean measuring 31 mm. There were more patients with T2 stage tumours 
(tumour size larger than 20mm) at 55.1%, compared with 38.0% with T1 stage. This 
series comprised 97 (28.1%) grade 1 tumours, 195 (56.5%) grade 2 tumours and 39 
(11.3%) grade 3 tumours. The most frequently detected lobular variant was the classical 
variant (31.3%), followed by solid (13%), pleomorphic (12.5%), alveolar (9.3%) and 
tubulo-lobular variant (8.4%). The remaining 25.5% tumours were of mixed subtypes, 
they mostly comprised classical mixed with other variants. Lymphovascular invasion (LVI) 
was detected in 68 patients (19.7%) and accompanying LCIS was present in 176 tumours 
(51.0%). Axillary lymph node metastases were detected in 139 (40.3%) out of 345 
patients, 52 (15.1%) of them had 1 to 3 metastatic lymph nodes (pN1), 38 (11.0%) had 4 
to 9 metastatic lymph nodes (pN2) and 49 (14.2%) had more than 9 metastatic lymph 







Table 3.2.1 Clinicopathological characteristics of the entire series (n=345). 
Characteristics No. of cases (%) 
   
Age group - years (mean 55, median 53, range 25-86 )  
≤ 40 26 (7.5) 
41-50 104 (30.1) 
51-60 111 (32.2) 
61-70 70 (20.3) 
>70 32 (9.3) 
   
Ethnicity   
Chinese 278 (80.6) 
Malay 23 (6.7) 
Indian 19 (5.5) 
Others 18 (5.2) 
Unknown 5 (1.4) 
   
Tumour size - mm (mean 31, median 25, range 1-130)  
≤20 131 (38.0) 
>20 190 (55.1) 
Unknown 24 (7.0) 
   
Histologic grade   
1 97 (28.1) 
2 195 (56.5) 
3 39 (11.3) 
not available 14 (4.1) 
   
Histologic type   
ILC 246 (71.3) 
Mixed ILC/IDC 99 (28.7) 
   
Lobular variant   
Classical 108 (31.3) 
Solid 45 (13.0) 
Alveolar 32 (9.3) 
Tubulo-lobular 29 (8.4) 
Pleomorphic 43 (12.5) 
Mixed 88 (25.5) 
   
Lymphovascular invasion   
Absent 277 (80.3) 
Present 68 (19.7) 





Table  3.2.1 Clinicopathological characteristics of the entire series (n=345) continued.  
Characteristics No. of cases (%) 
   
Associated LCIS   
Absent 74 (21.4) 
Present 176 (51.0) 
not available 95 (27.5) 
   
Lymph node status   
pN0 163 (47.2) 
pN1 52 (15.1) 
pN2 38 (11.0) 
pN3 49 (14.2) 
not sampled 43 (12.5) 
 
 




Localisation of immuno-markers in ILC is shown in Figure 3.3.1 to 3.3.3. Table 3.3.1 
shows the distribution of immuno-marker status in the entire series. For hormonal 
receptors ER and PR, positive tumours comprised 91.6% and 70.1% respectively. A small 
percentage (5.8%) of tumours overexpressed HER-2. Basal marker CK HMW was positive 
in 86.4% and CK14 was positive in 15.4% of tumours. EGFR was positive in 3.5% of the 
tumours. Mammaglobin was positive in 54.8% of tumours. Low proliferative fraction, 
measured by proportion of Ki-67 positive tumour cells, was detected in 25.5% of the 
tumours and high proliferative fraction in 11.0% of the tumours. There was absence of 
Ki-67 staining in 63.5% of the tumours. For prognostic comparison of Ki-67, positive 







Table 3.3.1 Immuno-markers status in entire series (n = 345). 
Immuno-markers 
Negative status                                      Positive status 
No. (%) No. (%) 
     
ER 29 (8.4) 316 (91.6) 
PR 103 (29.9) 242 (70.1) 
HER-2 325 (94.2) 20 (5.8) 
CK HMW 47 (13.6) 298 (86.4) 
CK14 292 (84.6) 53 (15.4) 
EGFR 333 (96.5) 12 (3.5) 
Mammaglobin 156 (45.2) 189 (54.8) 
     
Ki-67 219 (63.5) 
Low fraction (1-9%) 88 (25.5) 






            
             
              
Figure 3.3.1 Immunohistochemical expression of ER, PR and HER-2. 









             
              
                 
 
Figure 3.3.2 Immunohistochemical expression of basal markers CK HMW, CK14 and 
EGFR. 
Cytoplasmic localisation of CK14 and CK HMW and weak cytoplasmic membrane 








                 
 
         
 
 
Figure 3.3.3 Immunohistochemical expression of Ki-67 and Mammaglobin. 







Association of clinicopathological parameters and immuno-markers are illustrated from 
Table 3.3.2 to 3.3.9. ER negativity was significantly associated with disease presentation 
at older age (p=0.031), higher histologic grade (p=0.006), the pleomorphic variant 
(p<0.001) and the occurrence of lymphovascular invasion (LVI) (p=0.015) as shown in 
Table 3.3.2. PR positivity was associated with younger age (p<0.001), the classical 
variant (p=0.002), the presence of LVI (p=0.012) and lower LN stage (p=0.020) (Table 
3.3.3). Negative HER-2 status was associated with the absence of LVI (p=0.007) (Table 
3.3.4). Positive CK HMW status was associated with pN3 (p=0.002) (Table 3.3.5). 
Presence of accompanying LCIS was associated with positive CK14 status (p=0.002). 
There was weak association of CK14 negativity with higher LN stage (p=0.044) (Table 
3.3.6). Positive EGFR expression was associated with the pleomorphic variant (p=0.038) 
and negative EGFR expression was associated with absence of LVI (p=0.016) (Table 
3.3.7). High Ki-67 positive fraction was associated with the pleomorphic variant (p=0.001) 
(Table 3.3.8). There was no association of Mammaglobin expression with any better or 






Table 3.3.2 Association of hormonal marker ER status with clinicopathological 
characteristics. 
Characteristic 
ER status  
- +   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off       
<Mean age 10 (34.5) 178 (56.3) 0.031* 
≥Mean age 19 (65.5) 138 (43.7)   
        
Tumour size (mm)       
≤20 10 (34.5) 121 (38.3) 0.838 
>20 16 (55.2) 174 (55.1)   
        
Histologic grade       
1 2 (7.1) 95 (31.4) 0.006* 
2 19 (67.9) 176 (58.1)  
3 7 (25.0) 32 (10.6)   
        
Lobular variant       
Classical 5 (17.2) 103 (32.6) <0.001* 
Solid 2 (6.9) 43 (13.6)   
Alveolar 2 (6.9) 30 (9.5)   
Tubulo-lobular 1 (3.4) 28 (8.9)   
Pleomorphic 14 (48.3) 29 (9.2)   
Mixed 5 (17.2) 83 (26.3)   
        
Lymphovascular invasion       
Absent 18 (62.1) 259 (82.0) 0.015* 
Present 11 (37.9) 57 (18.0)   
        
Associated LCIS       
Absent 6 (20.7) 68 (21.5) 1.000 
Present 15 (51.7) 161 (50.9)   
        
Lymph node status       
pN0 14 (48.3) 149 (47.2) 0.074 
pN1 0 (0.0) 52 (16.5)   
pN2 5 (17.2) 33 (10.4)   
pN3 6 (20.7) 43 (13.6)   





Table 3.3.3 Association of hormonal marker PR status with clinicopathological 
characteristics.  
Characteristic 
PR status  
- +   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off       
<Mean age 41 (39.8) 147 (60.7) <0.001* 
≥Mean age 62 (60.2) 95 (39.3)   
        
Tumour size (mm)       
≤20 35 (34.0) 96 (39.7) 0.385 
>20 60 (58.3) 130 (53.7)   
        
Histologic grade       
1 22 (22.7) 75 (32.1) 0.147 
2 60 (61.9) 135 (57.7)   
3 15 (15.5) 24 (10.3)   
        
Lobular variant       
Classical 27 (26.2) 81 (33.5) 0.002* 
Solid 16 (15.5) 29 (12.0)   
Alveolar 7 (6.8) 25 (10.3)   
Tubulo-lobular 9 (8.7) 20 (8.3)   
Pleomorphic 24 (23.3) 19 (7.9)   
Mixed 20 (19.4) 68 (28.1)   
        
Lymphovascular invasion       
Absent 74 (71.8) 203 (83.9) 0.012* 
Present 29 (28.2) 39 (16.1)   
        
Associated LCIS       
Absent 25 (24.3) 49 (20.2) 0.654 
Present 53 (51.5) 123 (50.8)   
        
Lymph node status       
pN0 41 (39.8) 122 (50.4) 0.020* 
pN1 11 (10.7) 41 (16.9)   
pN2 14 (13.6) 24 (9.9)   
pN3 22 (21.4) 27 (11.2)   





Table 3.3.4 Association of HER-2 status with clinicopathological characteristics. 
Characteristic 
HER-2 status  
- +   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off       
<Mean age 173 (53.2) 15 (75.0) 0.066 
≥Mean age 152 (46.8) 5 (25.0)   
        
Tumour size (mm)       
≤20 127 (39.1) 4 (20.0) 0.296 
>20 178 (54.8) 12 (60.0)   
        
Histologic grade       
1 93 (29.8) 4 (21.1) 0.669 
2 183 (58.7) 12 (63.2)   
3 36 (11.5) 3 (15.8)   
        
Lobular variant       
Classical 103 (31.7) 5 (25.0) 0.371 
Solid 42 (12.9) 3 (15.0)   
Alveolar 31 (9.5) 1 (5.0)   
Tubulo-lobular 29 (8.9) 0 (0.0)   
Pleomorphic 38 (11.7) 5 (25.0)   
Mixed 82 (25.2) 6 (30.0)   
        
Lymphovascular invasion       
Absent 266 (81.8) 11 (55.0) 0.007* 
Present 59 (18.2) 9 (45.0)   
        
Associated LCIS       
Absent 69 (21.2) 5 (25.0) 0.773 
Present 166 (51.1) 10 (50.0)   
        
Lymph node status       
pN0 152 (46.8) 11 (55.0) 0.166 
pN1 52 (16.0) 0 (0.0)   
pN2 36 (11.1) 2 (10.0)   
pN3 44 (13.5) 5 (25.0)   





Table 3.3.5 Association of CK HMW status with clinicopathological characteristics.  
  CK HMW status   
Characteristic - +   
  No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off       
<Mean age 26 (55.3) 162 (54.4) 1.000 
≥Mean age 21 (44.7) 136 (45.6)   
        
Tumour size (mm)       
≤20 22 (46.8) 109 (36.6) 0.255 
>20 23 (48.9) 167 (56.0)   
        
Histologic grade       
1 14 (31.8) 83 (28.9) 0.810 
2 24 (54.5) 171 (59.6)   
3 6 (13.6) 33 (11.5)   
        
Lobular variant       
Classical 14 (29.8) 94 (31.5) 0.860 
Solid 4 (8.5) 41 (13.8)   
Alveolar 5 (10.6) 27 (9.1)   
Tubulo-lobular 3 (6.4) 26 (8.7)   
Pleomorphic 7 (14.9) 36 (12.1)   
Mixed 14 (29.8) 74 (24.8)   
        
Lymphovascular invasion       
Absent 40 (85.1) 237 (79.5) 0.435 
Present 7 (14.9) 61 (20.5)   
        
Associated LCIS       
Absent 8 (17.0) 66 (22.1) 0.819 
Present 17 (36.2) 159 (53.4)   
        
Lymph node status       
pN0 20 (42.6) 143 (48.0) 0.002* 
pN1 8 (17.0) 44 (14.8)   
pN2 12 (25.5) 26 (8.7)   
pN3 2 (4.3) 47 (15.8)   





Table 3.3.6 Association of CK14 status with clinicopathological characteristics 
  CK14 status   
Characteristic - +   
  No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off        
<Mean age 153 (52.4) 35 (66.0) 0.073 
≥Mean age 139 (47.6) 18 (34.0)   
        
Tumour size (mm)       
≤20 108 (37.0) 23 (43.4) 0.339 
>20 165 (56.5) 25 (47.2)   
        
Histologic grade       
1 80 (28.5) 17 (34.0) 0.345 
2 170 (60.5) 25 (50.0)   
3 31 (11.0) 8 (16.0)   
        
Lobular variant       
Classical 95 (32.5) 13 (24.5) 0.605 
Solid 37 (12.7) 8 (15.1)   
Alveolar 29 (9.9) 3 (5.7)   
Tubulo-lobular 25 (8.6) 4 (7.5)   
Pleomorphic 34 (11.6) 9 (17.0)   
Mixed 72 (24.7) 16 (30.2)   
        
Lymphovascular invasion       
Absent 235 (80.5) 42 (79.2) 0.852 
Present 57 (19.5) 11 (20.8)   
        
Associated LCIS       
Absent 69 (23.6) 5 (9.4) 0.002* 
Present 136 (46.6) 40 (75.5)   
        
Lymph node status       
pN0 140 (47.9) 23 (43.4) 0.044* 
pN1 39 (13.4) 13 (24.5)   
pN2 36 (12.3) 2 (3.8)   
pN3 44 (15.1) 5 (9.4)   





Table 3.3.7 Association of EGFR status with clinicopathological characteristics.  
  EGFR status   
Characteristic - +   
  No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off       
<Mean age 178 (53.5) 10 (83.3) 0.073 
≥Mean age 155 (46.5) 2 (16.7)   
        
Tumour size (mm)       
≤20 126 (37.8) 5 (41.7) 0.746 
>20 185 (55.6) 5 (41.7)   
        
Histologic grade       
1 95 (29.8) 2 (16.7) 0.283 
2 188 (58.9) 7 (58.3)   
3 36 (11.3) 3 (25.0)   
        
Lobular variant       
Classical 107 (32.1) 1 (8.3) 0.038* 
Solid 43 (12.9) 2 (16.7)   
Alveolar 31 (9.3) 1 (8.3)   
Tubulo-lobular 29 (8.7) 0 (0.0)   
Pleomorphic 38 (11.4) 5 (41.7)   
Mixed 85 (25.5) 3 (25.0)   
        
Lymphovascular invasion       
Absent 271 (81.4) 6 (50.0) 0.016* 
Present 62 (18.6) 6 (50.0)   
        
Associated LCIS       
Absent 72 (21.6) 2 (16.7) 1.000 
Present 170 (51.1) 6 (50.0)   
        
Lymph node status       
pN0 158 (47.4) 5 (41.7) 0.668 
pN1 49 (14.7) 3 (25.0)   
pN2 37 (11.1) 1 (8.3)   
pN3 46 (13.8) 3 (25.0)   





Table 3.3.8 Association of Ki-67 status with clinicopathological characteristics.  
  Ki-67 status   
Characteristic Low High   
  No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off      
<Mean age 171 (55.7) 17 (44.7) 0.228 
≥Mean age 136 (44.3) 21 (55.3)   
        
Tumour size (mm)       
≤20 80 (36.2) 51 (41.1)   
>20 123 (55.7) 67 (54.0) 0.556 
        
Histologic grade       
1 90 (30.7) 7 (18.4)   
2 170 (58.0) 25 (65.8) 0.264 
3 33 (11.3) 6 (15.8)   
        
Lobular variant       
Classical 100 (32.6) 8 (21.1) 0.001* 
Solid 39 (12.7) 6 (15.8)   
Alveolar 28 (9.1) 4 (10.5)   
Tubulo-lobular 26 (8.5) 3 (7.9)   
Pleomorphic 30 (9.8) 13 (34.2)   
Mixed 84 (27.4) 4 (10.5)   
        
Lymphovascular invasion       
Absent 247 (80.5) 30 (78.9) 0.830 
Present 60 (19.5) 8 (21.1)   
        
Associated LCIS       
Absent 63 (29.3) 11 (31.4) 0.842 
Present 152 (70.7) 24 (68.6)   
        
Lymph node status       
pN0 145 (53.9) 66 (54.5) 0.926 
pN1 46 (17.1) 16 (18.2)   
pN2 35 (13.0) 10 (9.1)   
pN3 43 (16.0) 19 (18.2)   





Table 3.3.9 Association of Mammaglobin status with clinicopathological 
characteristics. 
  Mammaglobin status   
Characteristic - +   
  No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off      
<Mean age 86 (55.1) 102 (54.0) 0.914 
≥Mean age 70 (44.9) 87 (46.0)   
        
Tumour size (mm)       
≤20 56 (35.9) 75 (39.7)   
>20 86 (55.1) 104 (55.0) 0.732 
        
Histologic grade       
1 40 (26.8) 57 (31.3)   
2 91 (61.1) 104 (57.1) 0.672 
3 18 (12.1) 21 (11.5)   
        
Lobular variant       
Classical 42 (26.9) 66 (34.9) 0.294 
Solid 18 (11.5) 27 (14.3)   
Alveolar 19 (12.2) 13 (6.9)   
Tubulo-lobular 14 (9.0) 15 (7.9)   
Pleomorphic 23 (14.7) 20 (10.6)   
Mixed 40 (25.6) 48 (25.4)   
        
Lymphovascular invasion       
Absent 122 (78.2) 155 (82.0) 0.416 
Present 34 (21.8) 34 (18.0)   
        
Associated LCIS       
Absent 30 (19.2) 44 (23.3) 0.675 
Present 78 (50.0) 98 (51.9)   
        
Lymph node status       
pN0 73 (46.8) 90 (47.6) 0.925 
pN1 22 (14.1) 30 (15.9)   
pN2 17 (10.9) 21 (11.1)   
pN3 24 (15.4) 25 (13.2)   









Differences between histologic types and clinicopathological characteristics were 
presented in Table 3.4.1. Characteristics that were significantly associated with histology 
type included grade, accompanying LCIS status and lobular variant. Mixed ILC/IDC was 
associated with higher grade compared to ILC (p<0.001). Pure ILC was associated with 
the classical variant (p<0.001), with higher proportion ILC being classical variant 
compared to mixed ILC/IDC. Accompanying LCIS was presented more frequently in ILC 





Table 3.4.1 Association of histologic type with clinicopathological characteristics.  
  Histologic Type   
Characteristic ILC Mixed ILC/IDC   
  No. (%) No. (%) p-value 
      
Mean Age (55 years) cut off     
<Mean age 137 (55.7) 51 (51.5) 0.550 
≥Mean age 109 (44.3) 48 (48.5)  
      
Tumour size (mm)      
≤20 90 (36.6) 41 (41.4) 0.534 
>20 137 (55.7) 53 (53.5)  
      
Histologic grade      
1 84 (35.6) 13 (13.7) <0.001* 
2 132 (55.9) 63 (66.3)  
3 20 (8.5) 19 (20.0)  
      
Lobular variant      
Classical 94 (38.2) 14 (14.1) <0.001* 
Solid 27 (11.0) 18 (18.2)  
Alveolar 21 (8.5) 11 (11.1)  
Tubulo-lobular 15 (6.1) 14 (14.1)  
Pleomorphic 31 (12.6) 12 (12.1)  
Mixed 58 (23.6) 30 (30.3)  
      
Lymphovascular invasion      
Absent 204 (82.9) 73 (73.7) 0.072 
Present 42 (17.1) 26 (26.3)  
      
Associated LCIS      
Absent 44 (17.9) 30 (30.3) 0.001* 
Present 142 (57.7) 34 (34.3)  
      
Lymph node status      
pN0 114 (46.3) 49 (49.5) 0.885 
pN1 38 (15.4) 14 (14.1)  
pN2 27 (11.0) 11 (11.1)  
pN3 37 (15.0) 12 (12.1)  





Association of histologic type with immuno-markers was presented in Table 3.4.2. There 
was a weak association of mixed ILC/IDC with HER-2 positivity (p=0.041). 
 
Table 3.4.2 Association of histologic type with immuno-markers. 
Immuno-marker Status 
Histologic Type   
ILC Mixed ILC/IDC   
No. (%) No. (%) p-value 
         
ER - 18 (7.3) 11 (11.1) 0.284 
  + 228 (93.1) 88 (88.9)   
         
PR - 73 (29.8) 30 (30.3) 0.897 
  + 173 (70.6) 69 (69.7)   
         
HER-2 - 236 (96.3) 89 (89.9) 0.041* 
  + 10 (4.1) 10 (10.1)   
         
CK HMW - 31 (12.7) 16 (16.2) 0.389 
  + 215 (87.8) 83 (83.8)   
         
CK 14 - 204 (83.3) 88 (88.9) 0.189 
  + 42 (17.1) 11 (11.1)   
         
EGFR - 239 (97.6) 95 (96.0) 0.519 
  + 7 (2.9) 4 (4.0)   
         
Mammaglobin - 108 (44.1) 48 (48.5) 0.474 
  + 138 (56.3) 51 (51.5)   
         
Ki-67 Low 221 (72.0) 25 (65.8) 0.449 
  High 86 (28.0) 13 (34.2)   













The pleomorphic variant made up 12.5% (43/345) of all tumours (Table 3.5.1). It was 
associated with higher tumour grade. From Table 3.5.2, grade 2 tumours made up 73.8% 
of the pleomorphic variant compared to 56.7% of non-pleomorphic and grade 3 
tumours made up 19.0% of the pleomorphic variant versus 10.7% of the non-
pleomorphic variant (p=0.002).  
 
Table 3.5.1 Distribution of pleomorphic variant in the entire series.  
Pleomorphic category No. (%) 
   
Pleomorphic 43 (12.5) 






Table 3.5.2 Association of pleomorphic variant with clinicopathological characteristics.  
Characteristic 
Pleomorphic Non-pleomorphic   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off      
<Mean age 18 (41.9) 170 (56.3) 0.101 
≥Mean age 25 (58.1) 132 (43.7)   
        
Tumour size (mm)       
≤20 12 (27.9) 119 (39.4) 0.191 
>20 29 (67.4) 161 (53.3)   
        
Histologic grade       
1 3 (7.1) 94 (32.5) 0.002* 
2 31 (73.8) 164 (56.7)   
3 8 (19.0) 31 (10.7)   
        
Lymphovascular invasion       
Absent 30 (69.8) 247 (81.8) 0.099 
Present 13 (30.2) 55 (18.2)   
        
Associated LCIS       
Absent 8 (18.6) 66 (21.9) 0.427 
Present 27 (62.8) 149 (49.3)   
        
Lymph node status       
pN0 15 (34.9) 148 (49.0) 0.133 
pN1 4 (9.3) 48 (15.9)   
pN2 5 (11.6) 33 (10.9)   
pN3 10 (23.3) 39 (12.9)   






Table 3.5.3 shows the association of the pleomorphic variant with immuno-markers. The 
pleomorphic variant was associated with ER (p<0.001) and PR negative status (p<0.001). 
Among the pleomorphic tumours, 32.6% were ER negative tumours compared to only 
5.0% of non-pleomorphic tumours. PR negativity was present in 55.8% of pleomorphic 
tumours compared to 26.2% of non-pleomorphic tumours.  There were significantly 
more EGFR positive tumours among the pleomorphic variant (11.6%) than non-
pleomprphic variant (2.0%) (p=0.006). There were higher proportions of tumours with 
high Ki-67 positive fraction among the pleomorphic variant (30.2%) than non-






Table 3.5.3 Association of the pleomorphic variant with immuno-markers. 
Immuno-marker Status 
Pleomorphic Non-pleomorphic   
No. (%) No. (%) p-value 
         
ER - 14 (32.6) 15 (5.0) <0.001* 
  + 29 (67.4) 287 (95.0)   
         
PR - 24 (55.8) 79 (26.2) <0.001* 
  + 19 (44.2) 223 (73.8)   
         
HER-2 - 38 (88.4) 287 (95.0) 0.088 
  + 5 (11.6) 15 (5.0)   
         
CK HMW - 7 (16.3) 40 (13.2) 0.634 
  + 36 (83.7) 262 (86.8)   
         
CK14 - 34 (79.1) 258 (85.4) 0.265 
  + 9 (20.9) 44 (14.6)   
         
EGFR - 38 (88.4) 296 (98.0) 0.006* 
  + 5 (11.6) 6 (2.0)   
         
Mammaglobin - 23 (53.5) 133 (44.0) 0.256 
  + 20 (46.5) 169 (56.0)   
       
Ki-67 Low 30 (69.8) 277 (91.7) <0.001* 
  High 13 (30.2) 25 (8.3)   










Triple negativity, where ER, PR and HER-2 status is negative, according to defined cut-
offs, was seen in 20 (5.8%) tumours. The remaining 325 (94.2%) tumours were grouped 
as non-triple negative tumours (Table 3.6.1).  
 
Table 3.6.1 Distribution of triple negativity in the entire series. 
Triple negative category No. (%)  
    
Triple negative ILC 20 (5.8)  
Non-triple negative ILC 325 (94.2)  
 
 
Triple negativity had less favourable characteristics. As seen in Table 3.6.2, the 
proportion of older patients was 75.0% for triple negative ILC and 43.7% for non-triple 
negative ILC (p=0.009). There are more grade 3 tumours among the triple negative ILC 
(21.1%) compared to non-triple negative ILC (11.2%) (p=0.045). Higher proportion 
(45.0%) of triple negative ILC were pleomorphic variant compared to 10.5% of non-triple 






Table 3.6.2 Association of triple negativity with clinicopathological characteristics. 
Characteristic 
Triple negative Non-triple negative   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off      
<Mean age 5 (25.0) 183 (56.3) 0.009* 
≥Mean age 15 (75.0) 142 (43.7)   
        
Tumour size (mm)       
≤20 8 (40.0) 123 (37.8)   
>20 10 (50.0) 180 (55.4) 0.807 
        
Histologic grade       
1 1 (5.3) 96 (30.8)   
2 14 (73.7) 181 (58.0) 0.045* 
3 4 (21.1) 35 (11.2)   
        
Lobular variant       
Pleomorphic 9 (45.0) 34 (10.5) <0.001* 
Non-pleomorphic 11 (55.0) 291 (89.5)   
        
Lymphovascular invasion       
Absent 13 (65.0) 264 (81.2) 0.086 
Present 7 (35.0) 61 (18.8)   
        
Associated LCIS       
Absent 4 (20.0) 70 (21.5) 1.000 
Present 11 (55.0) 165 (50.8)   
        
Lymph node status       
pN0 9 (45.0) 154 (47.4) 0.144 
pN1 0 (0.0) 52 (16.0)   
pN2 4 (20.0) 34 (10.5)   
pN3 4 (20.0) 45 (13.8)   






Table 3.6.3 illustrates the association of triple negative ILC with immuno-markers. CK 
HMW negative status was weakly associated with triple negative ILC (p=0.040), where 
CK HMW was negative in 30.0% of triple negative ILC and in 12.6% of non-triple negative 
ILC. Compared with non-triple negative ILC, triple negative ILC were much more likely to 
be Mammaglobin negative (80.0% of triple negative ILC versus 43.1% of non-triple 
negative ILC; p=0.002).  
 
Table 3.6.3 Association of triple negativity with immuno-markers. 
Immuno-marker Status 
Triple negative Non-triple negative   
No. (%) No. (%) p-value 
         
CK HMW - 6 (30.0) 41 (12.6) 0.040* 
  + 14 (70.0) 284 (87.4)   
         
CK14 - 16 (80.0) 276 (84.9) 0.526 
  + 4 (20.0) 49 (15.1)   
         
EGFR - 19 (95.0) 315 (96.9) 0.487 
  + 1 (5.0) 10 (3.1)   
         
Mammaglobin - 16 (80.0) 140 (43.1) 0.002* 
  + 4 (20.0) 185 (56.9)   
         
Ki-67 Low 19 (95.0) 288 (88.6) 0.710 
  High 1 (5.0) 37 (11.4)   














According to previous criteria established by Thike et al., basal phenotype is defined as 
tumours expressing positivity for at least one of the following markers: CK HMW, CK14 
or EGFR (Thike et al. 2010). Based on this definition, 98.6% of tumours were basal-like. 
This proportion was too high and might be as a result of the wide spectrum reactivity of 
CK HMW cocktail (clone: 34βE12). The expression of 34βE12, incorporating CK1, 5, 10 
and 14, may be non-specific for basal expression in ILC. Using the criteria of positivity for 
CK14 and/or EGFR, the proportion of basal phenotype was reduced to a more realistic 
proportion of 17.4%. This latter definition was adopted to test the association of basal 
phenotype with clinicopathological characteristics and immuno-markers (Table 3.7.1).  
 
Table 3.7.1 Distribution of basal phenotype in the entire series according to different 
definition. 
Basal-like phenotype No. (%) 
   
Based on positivity of CK HMW and/or CK14 and/or EGFR   
Basal phenotype 340 (98.6) 
Non-basal phenotype 5 (1.4) 
   
Based on positivity of CK14 and/or EGFR   
Basal phenotype 60 (17.4) 
Non-basal phenotype 285 (82.6) 
 
 
Comparing tumours with basal and non-basal phenotype, the latter were more frequent 





phenotype was significantly associated with presence of LCIS (71.7% of basal-like versus 
46.7% of non basal-like; p=0.003).  
 
 
Table 3.7.2 Association of basal phenotype with clinicopathological characteristics. 
Characteristic 
Basal phenotype Non-basal phenotype   
No. (%) No. (%) p-value 
        
Mean Age (55 years) cut off      
<Mean age 40 (66.7) 148 (51.9) 0.046* 
≥Mean age 20 (33.3) 137 (48.1)   
        
Tumour size (mm)       
≤20 25 (41.7) 106 (37.2) 0.368 
>20 29 (48.3) 161 (56.5)   
        
Histologic grade       
1 18 (31.6) 79 (28.8) 0.720 
2 31 (54.4) 164 (59.9)   
3 8 (14.0) 31 (11.3)   
        
Lobular variant       
Pleomorphic 12 (20.0) 31 (10.9) 0.082 
Non-pleomorphic 48 (80.0) 254 (89.1)   
        
LVI       
Absent 47 (78.3) 230 (80.7) 0.721 
Present 13 (21.7) 55 (19.3)   
        
Associated LCIS       
Absent 6 (10.0) 68 (23.9) 0.003* 
Present 43 (71.7) 133 (46.7)   
        
Lymph node status       
pN0 27 (45.0) 136 (47.7) 0.080 
pN1 14 (23.3) 38 (13.3)   
pN2 3 (5.0) 35 (12.3)   
pN3 6 (10.0) 43 (15.1)   





Table 3.7.3 shows no association established between basal phenotype and immuno-
markers. 
 
Table 3.7.3 Association of basal phenotype with immuno-markers. 
Immuno-markers Status 
       Basal-like  Non Basal-like   
No. (%) No. (%) p-value 
         
ER - 6 (10.0) 23 (8.1) 0.611 
  + 54 (90.0) 262 (91.9)   
         
PR - 16 (26.7) 87 (30.5) 0.642 
  + 44 (73.3) 198 (69.5)   
         
HER-2 - 57 (95.0) 268 (94.0) 1.000 
  + 3 (5.0) 17 (6.0)   
         
CK HMW - 4 (6.7) 43 (15.1) 0.098 
  + 56 (93.3) 242 (84.9)   
         
Mammaglobin - 25 (41.7) 131 (46.0) 0.571 
  + 35 (58.3) 154 (54.0)   
         
Ki-67 Low 51 (85.0) 256 (89.8) 0.264 
  High 9 (15.0) 29 (10.2)   












From various gene expression studies, the most powerful discriminator genes for the 
different molecular subtypes are the expression of luminal epithelial specific gene, ESR1 
gene which encodes for estrogen receptor and ERBB2 which encodes for HER-2/neu 
(van't Veer et al. 2002;West et al. 2001;Sorlie et al. 2003). Stemming from molecular 
profiling evidence, use of surrogate immunohistochemical markers ER, PR and HER-2 
was applied to classify tumours into the modified molecular subtypes. Table 3.8.1 shows 
the criteria used for categorisation of molecular subtypes according to surrogate 
immunohistochemical markers ER, PR and HER-2 and the distribution of tumours. 
Majority were luminal A-like (88.4%), 4.1% were luminal B-like and 1.7% were HER-2 
overexpressing. Triple negative (ER -, PR - and HER-2 -) breast cancers often overlap 
significantly with the basal molecular subtype. If we incorporated positivity for basal 
markers CK14 and/or EGFR in this group, our proportion of basal-like molecular subtype 
would be 1.2%. This compares against 17.4% of all tumours in the series expressing 
basal markers CK14 and/or EGFR regardless of triple negativity. Sixteen (4.6%) of the 
triple negative tumours were also negative for CK14 and EGFR. This group was labeled 








Table 3.8.1 Criteria used for molecular subtype and the distribution of molecular 
subtype in the entire series. 
Molecular subtype Criteria used No. (%) 
    
Luminal A ER+/PR+/HER-2- or  ER+/PR-/HER-2- 
or  ER-/PR+/HER-2- 
305 (88.4) 
    
Luminal B ER+/PR+/HER-2+ or  ER+/PR-/HER-2+ 
or  ER-/PR+/HER-2+  
14 (4.1) 
    
HER-2 overexpressing ER-/PR-/HER-2+ 6 (1.7) 
    
Basal-like ER-/PR-/HER-2-/CK14+ and/or EGFR+ 4 (1.2) 
    
Unclassified (Penta negative) ER-/PR-/HER-2-/CK14-/EGFR- 16 (4.6) 
 
Analysis of molecular subtype and clinicopathological characteristics was shown in Table 
3.8.2. Basal-like and penta negative molecular subtypes were associated with older age 
(p=0.030). Proportion of patient age older than the mean was 75.0% in the basal-like 
and penta-negative categories compared to 44.9% in luminal A, 21.4% in luminal B and 
33.3% in HER-2 overexpressing subtype. There was a significantly higher proportion of 
non-pleomorphic variant in luminal A (90.5%) and luminal B (85.7%) subtypes compared 
to HER-2 overexpressing, basal-like and penta negative molecular subtypes (p<0.001).   







Table 3.8.2 Association of molecular subtype with clinicopathological characteristics.  
Characteristic 
Molecular category  
p-value 
Luminal A Luminal B 
HER-2 
overexpressing  Basal-like 
Penta 
negative 
No. (%) No. (%) No. (%) No. (%) No. (%) 
              
Mean Age (55 years) cut off           
<Mean age 168 (55.1) 11 (78.6) 4 (66.7) 1 (25.0) 4 (25.0) 0.030* 
≥Mean age 137 (44.9) 3 (21.4) 2 (33.3) 3 (75.0) 12 (75.0)   
              
Tumour size (mm)             
≤20 119 (39.0) 3 (21.4) 1 (16.7) 2 (50.0) 6 (37.5) 0.746 
>20 168 (55.1) 8 (57.1) 4 (66.7) 2 (50.0) 8 (50.0)   
              
Histologic grade             
1 92 (30.2) 3 (21.4) 1 (16.7) 0 (0.0) 1 (6.3) 0.264 
2 169 (55.4) 9 (64.3) 3 (50.0) 3 (75.0) 11 (68.8)   
3 32 (10.5) 1 (7.1) 2 (33.3) 1 (25.0) 3 (18.8)   
              
Lobular variant             
Pleomorphic 29 (9.5) 2 (14.3) 3 (50.0) 2 (50.0) 7 (43.8) <0.001* 
Non-pleomorphic 276 (90.5) 12 (85.7) 3 (50.0) 2 (50.0) 9 (56.3)   
              
LVI             
Absent 253 (83.0) 7 (50.0) 4 (66.7) 2 (50.0) 11 (68.8) 0.008* 
Present 52 (17.0) 7 (50.0) 2 (33.3) 2 (50.0) 6 (37.5)   
              
Associated LCIS             
Absent 65 (21.3) 3 (21.4) 2 (33.3) 0 (0.0) 4 (25.0) 0.705 
Present 155 (50.8) 8 (57.1) 2 (33.3) 3 (75.0) 8 (50.0)   
              
Lymph node status             
pN0 143 (46.9) 9 (64.3) 2 (33.3) 2 (50.0) 7 (43.8) 0.141 
pN1 52 (17.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   
pN2 32 (10.5) 1 (7.1) 1 (16.7) 0 (0.0) 4 (25.0)   
pN3 40 (13.1) 3 (21.4) 2 (33.3) 2 (50.0) 2 (12.5)   






HER-2 overexpressing, basal-like and the penta-negative molecular subtypes were 
associated with negative Mammoglobin status (p=0.005) according to Table 3.8.3. There 
were significant higher proportions of Mammaglobin negative tumours in the HER-2 
overexpressing (83.3%), basal-like (75.0%) and penta negative (81.3%) subtypes 
compared to luminal A (42.0%) and luminal B (50.0%). 
 





Luminal A Luminal B 
HER-2 
overexpressing  Basal-like 
Penta 
negative 
No. (%) No. (%) No. (%) No. (%) No. (%) 
            
Mammaglobin             
- 128 (42.0) 7 (50.0) 5 (83.3) 3 (75.0) 13 (81.3) 0.005* 
+ 177 (58.0) 7 (50.0) 1 (16.7) 1 (25.0) 3 (18.8)   
              
Ki-67             
low 198 (64.9) 10 (71.4) 3 (50.0) 1 (25.0) 9 (56.3) 0.404 








3.9 Immunohistochemical expression of E-cadherin and p120 catenin 
 
 
In this series, 111/345 (32.2%) of lobular tumours showed E-cadherin positivity and 
67.8% of the tumours were negative for E-cadherin (Table 3.9.1). The percentage of 
positive cells ranged from 5% to 100%. This positive but aberrant expression of E-
cadherin ranged from incomplete membrane to perimembranous cytoplasmic staining 
(Figure 3.9.1). Majority (80.3%) of the tumours had aberrant cytoplasmic localisation of 
p120 catenin, 18.8% of the tumours expressed both cytoplasmic and membrane 
localisation and 3 tumours (0.9%) showed complete loss of p120 catenin cytoplasmic 
and membrane expression. 
 
Table 3.9.1 E-cadherin and p120 catenin expression in ILC. 
Immuno-marker No.  (%) 
   
E-cadherin   
      Aberrant expression 111 (32.2) 
      Negative expression 234 (67.8) 
   
p120 catenin   
      Cytoplasmic only 277 (80.3) 
      Cytoplasmic and membrane 65 (18.8) 











Figure 3.9.1 Varying immunohistochemical expression of E-cadherin in ILC. 
 
 
(B) Perimembranous cytoplasmic 
staining in the absence of complete 
circumferential membrane staining 
 
(C) Weak incomplete membrane 
staining in a proportion of tumour 
cells. 
 









Among the E-cadherin negative tumours, 226/234 (96.6%) had cytoplasmic 
accumulation of p120 catenin, 5/234 (2.1%) expressed both cytoplasmic and membrane 
p120 catenin and 3/234 (0.9%) had complete loss of p120 catenin expression. Among 
the tumours that expressed E-cadherin, 51/111 (45.9%) expressed cytoplasmic p120, 
60/111 (54.1%) showed both cytoplasm and membrane expression. The diffuse 
cytoplasmic expression p120 catenin was strongly associated with negative E-cadherin 
expression. p120 catenin cytoplasmic localisation ranged from weakly to moderately 
staining intensity with patchy to homogenous diffuse pattern (Figure 3.9.2). 
 
 
Table 3.9.2 p120 catenin cytoplasmic and cytoplasmic membrane localisation among 
E-cadherin positive and negative tumours. 





Aberrant expression  
(n=111) 
No. (%) No. (%) 
     
Cytoplasmic only 226 (96.6) 51 (45.9) 
Cytoplasmic and membrane 5 (2.1) 60 (54.1) 








(A) E-cadherin negative tumour with strong diffuse p120 catenin cytoplasmic 
localisation. 
 
(B) Aberrant E-cadherin patchily positive tumour with weakly positive cytoplasmic 
membrane and cytoplasmic localisation of p120 catenin. 
 
(C) Tumour with negative E-cadherin and p120 catenin expression 
Figure 3.9.2 Differential expression of E-cadherin and p120 catenin in ILC. 
 
(A) E-cadherin (A) p120 catenin 
(B) E-cadherin (B) p120 catenin 





Differences were identified between tumours with E-cadherin expression (aberrant) and 
E-cadherin negative tumours. E-cadherin positivity was more likely to be associated with 
presence of LVI (p=0.021) and absence of accompanying LCIS (p=0.001) (Table 3.9.3). 
 
Table 3.9.3 Association of E-cadherin status with clinicopathological characteristics. 
  E-cadherin   
Characteristic -   +     
  No. (%) No. (%) p-value 
        
Mean Age cut off       
<Mean age 120 (51.3) 68 (61.3) 0.084 
≥Mean age 114 (48.7) 43 (38.7)   
        
Tumour size       
≤20 87 (40.3) 44 (41.9) 0.809 
>20 129 (59.7) 61 (58.1)   
        
Histologic grade       
1 67 (29.9) 30 (28.0) 0.277 
2 135 (60.3) 60 (56.1)   
3 22 (9.8) 17 (15.9)   
        
Lobular variant       
Pleomorphic 35 (15.0) 8 (7.2) 0.054 
Non-pleomorphic 199 (85.0) 103 (92.8)   
        
LVI       
Absent 196 (83.8) 81 (73.0) 0.021* 
Present 38 (16.2) 30 (27.0)   
        
Associated LCIS       
Absent 41 (23.2) 33 (45.2) 0.001* 
Present 136 (76.8) 40 (54.8)   
        
Lymph node status       
pN0 119 (58.0) 44 (45.4) 0.127 
pN1 32 (15.6) 20 (20.6)   
pN2 21 (10.2) 17 (17.5)   
pN3 33 (16.1) 16 (16.5)   





3.10 Patients’ outcome : Kaplan-meier survival analyses 
 
A total of 345 patients had mean follow-up of 76.6 ± 50.1 months (range -1 to 199 
months) for disease-free survival (DFS) and 87.0 ± 50.6 months (range 0 to 200 months) 
for overall survival (OS). The rate of local recurrence and distant metastasis was 3.77 per 
100 patient year.  The rate of all causes of death was 2.00 per 100 patient year. The DFS 
at 5 years was 80.0% (95% confident interval 72.0 - 88.0%) and the OS at 5 years was 
87.8% (95% confident interval 83.9 - 91.6%). Characteristics that demonstrated 
significant differences (p<0.05) in outcome were indicated with *. 
 
3.10.1  Disease-Free Survival 
 
Tumour size had prognostic value for DFS (p<0.001), patients with tumour size greater 
than 20mm had less favourable DFS (Figure 3.10.1). 
 
Figure 3.10.1 Relative cumulative DFS of ILC patients with respect to tumour size.  
Tumour 









Patients with grade 1 tumours had better disease-free outcome compared to patients 




Figure 3.10.2 Relative cumulative DFS of ILC patients with respect to histologic grade. 
 
 
Patients with presence of LVI (p=0.015)(Figure 3.10.3) and positive axillary lymph node 


































HER-2 overexpressing molecular subtype has the worst DFS (p=0.008) compared to the 
other molecular subtypes (Figure 3.10.5). 
 
 




The pleomorphic variant had a slightly lower probability of survival compared to non-
pleomorphic variants but this difference was not significant (Figure 3.10.9). 
Characteristics that had no effect on DFS were age, presence of accompanying LCIS, 

















Figure 3.10.7 Relative cumulative DFS of ILC patients with respect to LCIS. 
Mean Age cut off 
<Mean age  
≥Mean age 
<Mean age censored 

























Figure 3.10.10 Relative cumulative DFS of ILC patients with respect to TNBC category. 
 
 









PR positivity was associated with better DFS (p=0.005)(Figure 3.10.12). A worse DFS was 






























Figure 3.10.13 Relative cumulative DFS of ILC patients with respect to HER-2 status. 
 
 
ER, p120 catenin, aberrant E-cadherin, Ki-67, Mammaglobin, EGFR, CK14 and CK HMW 
status did not influence the disease-free outcomes of ILC patients as illustrated in the 






















































































3.10.2  Overall Survival 
 
Survival analysis comparing age (Figure 3.10.21) established that patients who were 








Larger tumour size (>20mm) was significantly associated with poorer overall outcome 








Mean Age cut off 
<Mean age  
≥Mean age 
<Mean age censored 







Figure 3.10.22 Relative cumulative OS of ILC patients with respect to tumour size.  
 
 
Presence of LVI (p<0.001) (Figure 3.10.23) and absence of accompanying LCIS (p=0.004) 






































Figure 3.10.25 Relative cumulative OS of ILC patients with respect to LN status.  
 
 
Tumours with non-basal phenotype had better overall outcome compared to basal-like 
tumours as seen from the lower cumulative survival curve (Figure 3.10.26), however, 















Similar to DFS, HER-2 overexpressing subtype had a poorer outcome in OS but this 
















































Patients with PR positive tumours had a better prognosis than those with PR negative 
tumours (p=0.013) (Figure 3.10.30).  
 
 




Expression of all other immuno-markers showed no prognostic value to the OS of 






































Tumours that lacked expression of basal markers (CK14, CK HMW and EGFR) seemed to 





























In summary, the most important prognostic determinants for DFS were tumour size, 
histologic grade, occurrence of LVI, lymph node status, HER-2 overexpressing subtype, 
PR and HER-2 status. For OS, they were age, tumour size, occurrence of LVI, concurrent 
LCIS, lymph node status and PR status. 
 
3.11 Patients’ outcome : Univariate and multivariate analyses 
 
On univariate analyses, variables that were significantly associated with reduced DFS 
were tumour size, histologic grade, LVI, lymph node status, PR and HER-2 status. For 
overall survival (OS), characteristics that had significant prognostic value were tumour 
size, LVI, accompanying LCIS, lymph node status and PR status. Increased risk of local 
recurrences and distant metastasis and diminished OS were detected in patients 
harbouring bigger tumours. Patients with >20 mm tumours were at a 2.85 times 
(p<0.001) increased risk of metastasis and 5.75 times (p<0.001) increased risk of death 
compared to patients with ≤20mm tumours. Higher histological grade was significantly 
associated with decreased DFS. Grade 2 tumours had 2.02 times (p=0.018) more 
likelihood of recurrence than grade 1 tumours and grade 3 tumours had 3.90 times 
(p<0.001) the risk of recurrence. However, this tendency was not significantly reflected 
in the risk of death (Grade 2 vs. grade 1 HR=1.69, p=0.138; Grade 3 vs. grade 1 HR=2.26, 
p=0.080). Patients with LVI had 1.85 times higher risk of disease recurrence (p=0.016) 
and 3.06 times increased risk of death compared with patients without LVI (p<0.001). 





death compared to absence of LCIS however only risk of death was significantly reduced, 
by 63% (p=0.006). There was an increased risk for recurrence and death for patients 
with axillary lymph node involvement in an incremental manner. The higher the number 
of axillary lymph nodes involved, the higher the risk for recurrence and death. Hazard 
ratio for pN1 was 2.59, pN2 was 3.57 and pN3 was 5.75 compared to pN0 for DFS. 
Hazard ratio for pN1 was 2.88, pN2 was 4.26 and pN3 was 7.12 compared to pN0 for OS. 
HR was significant comparing all strata of lymph node status against pN0. Positive PR 
status had protective effect on survival. PR positivity had 47% improvement in DFS 
(p=0.006) and 50% improvement in OS (p=0.015). Overexpression of HER-2 protein had 
detrimental effect on DFS, with HER-2 positive patients having 2.23 times higher risk of 











Table 3.11.1 Univariate Cox regression model for disease-free survival (DFS) and 




HR (95% CI) p-value HR (95% CI) p-value 
                
Tumour size (mm)               
≤20 1.00     <0.001* 1.00     <0.001* 
>20 2.85 (1.58 - 5.12)  5.75 (2.27 - 14.57)  
                
Histologic grade               
1 1.00     0.001* 1.00     0.180 
2 2.02 (1.13 - 3.62) 0.018* 1.69 (0.85 - 3.36) 0.138 
3 3.90 (1.92 - 7.92) <0.001* 2.26 (0.91 - 5.65) 0.080 
                
LVI               
Absent 1.00     0.016* 1.00     <0.001* 
Present 1.85 (1.12 - 3.06)  3.06 (1.71 - 5.50)  
                
Associated LCIS               
Absent 1.00     0.185 1.00     0.006* 
Present 0.67 (0.37 - 1.21)  0.37 (0.18 - 0.76)  
                
Lymph node status               
pN0 1.00     <0.001* 1.00     <0.001* 
pN1 2.59 (1.32 - 5.11) 0.006* 2.88 (1.14 - 7.27) 0.025* 
pN2 3.57 (1.79 - 7.12) <0.001* 4.26 (1.69 - 10.74) 0.002* 
pN3 5.75 (3.12 - 10.58) <0.001* 7.12 (3.11 - 16.31) <0.001* 
                
PR               
- 1.00     0.006* 1.00     0.015* 
+ 0.53 (0.34 - 0.83)  0.50 (0.28 - 0.87)  
                
HER-2               
- 1.00     0.031* 1.00     0.449 






On multivariate analyses, variables that have significant independent association with 
reduced DFS were tumour size, histologic grade and lymph node status. The only 
variable that was significantly associated with reduced OS was lymph node status. Based 
on this Cox regression model, tumour size >20mm was shown to be independently 
associated with reduced DFS (HR=3.18, p=0.012). Grade 3 tumours had 3.04 times the 
risk of disease recurrence (p=0.021) compared to grade 1 tumours after adjusting for 
confounding variables in the model. LN status remained independently associated with 
increased risk of metastasis, recurrence and death. Patients with more than 9 axillary 
lymph node metastasis (pN3) had 3.80 (p=0.002) times the risk for disease recurrence 
and 5.46 (p=0.007) times the risk for death compared to patients with no metastatic 
lymph node. Lymhovascular invasion, associated LCIS, PR and HER-2 status were no 






Table 3.11.2 Multivariate Cox regression model for disease-free survival (DFS) and 




HR (95% CI) p-value HR (95% CI) p-value 
           
Tumour size (mm)          
≤20 1.00   0.012* 1.00   0.061 
>20 3.18 (1.29 - 7.84)  3.26 (0.95 - 11.25)   
           
Histologic grade          
1 1.00   0.033* 1.00   0.780 
2 1.46 (0.60 - 3.58) 0.389 0.72 (0.26 - 2.03) 0.537 
3 3.04 (1.12 - 8.26) 0.021* 0.95 (0.27 - 3.35) 0.940 
           
LVI          
Absent 1.00   0.712 1.00   0.487 
Present 0.87 (0.42 - 1.82)  1.35 (0.58 - 3.14)   
           
Associated LCIS          
Absent 1.00   0.812 1.00   0.241 
Present 1.09 (0.55 - 2.14)  0.62 (0.27 - 1.39)   
           
Lymph node status          
pN0 1.00   0.021* 1.00   0.042* 
pN1 2.24 (0.85 - 5.88) 0.101 3.91 (1.02 - 14.97) 0.047* 
pN2 2.24 (0.80 - 6.23) 0.123 4.89 (0.52 - 11.54) 0.018* 
pN3 3.80 (1.64 - 8.77) 0.002* 5.46 (1.34 - 16.97) 0.007* 
           
PR          
- 1.00   0.202 1.00   0.274 
+ 0.66 (0.34 - 1.25)  0.63 (0.28 - 1.44)   
           
HER-2          
- 1.00   0.188 1.00   0.440 








3.12 Pattern of metastatic dissemination 
 
Disease recurrences and metastases were detected in 83/345 (24.1%) of patients. 
Locoregional recurrence following primary surgery occurred in 20 (24.1%) patients and 
63 (75.9%) had distant metastasis. The most frequent distant site of dissemination was 
to the bone (33.7%), followed by lung/pleura (4.8%). There was no difference in the 
sites of distant metastasis between ILC and mixed ILC/IDC. 
 
Table 3.12.1 Locoregional recurrence and distant sites of first recurrence (n=83).  
  All 
ILC  
(n=64) 
Mixed ILC/ IDC 
(n=19)   
Sites No. (%) No. (%) No. (%) p-value 
        
Locoregional recurrence 20 (24.1) 15 (18.1) 5 (6.0) 1.000 
        
Bone 28 (33.7) 24 (28.9) 4 (4.8) 0.270 
Lung/pleural 4 (4.8) 2 (2.4) 2 (2.4) # 
Other nodes 3 (3.6) 3 (3.6) 0 (0.0) # 
Liver 3 (3.6) 3 (3.6) 0 (0.0) # 
Skin/mucosa 2 (2.4) 2 (2.4) 0 (0.0) # 
Pericardium 1 (1.2) 0 (0.0) 1 (1.2) # 
Unknown site (neck, abdomen) 2 (2.4) 1 (1.2) 1 (1.2) # 
Multiple 20 (24.1) 14 (16.9) 6 (7.2) 0.385 
Other nodes:  inclusive of  cervical, clavicular and inguinal lymph nodes 
Locoregional recurrence: inclusive of supraclavicular lymph node, chest skin, chest wall, 
axillary lymph node, ipsilateral and contralateral breast recurrence 
Multiple: multiple metastatic sites in the same patient 









4 Discussion  
 
The objective of the present study is to characterise more comprehensively the 
clinicopathological and biological phenotype of ILC to understand the behaviour which 
can potentially impact on management strategies.  
 
4.1 Significance of clinicopathological characteristics 
 
This current study re-emphasizes some of the clinicopathological features of ILC, such as 
its presentation in older women (highest proportion at age group 50-60), high 
proportion of low grade tumours and low frequency of lymphovascular invasion. 
 
Arpino et al. (Arpino et al. 2004) reported 80.6% and Pestalozzi et al. (Pestalozzi et al. 
2008) reported 59.1% of their ILC cases to be above 50 years old at diagnosis and this 
series similarly has a high proportion of women diagnosed at an age above 50 years 
(61.8%). Presentation of the disease at older age and larger tumours may be a result of 
the greater obscurity on detecting ILC on mammography leading to delay in diagnosis 
(Karl N. Krecke 1983). This may be attributed to the diffuse infiltrative growth pattern 
which invades the stroma in single files without stromal desmoplasia and the failure to 
form a discrete mass. When association of age with clinicopathological parameters was 
performed using the average menopausal age of 50 years commmonly reported in 





differences in results other than the loss of association of age with ER, TNBC and 
additional significant association with EGFR and CK14. However, on multivariate analysis, 
age had no independent prognostic significance for all cut-offs. 
 
Comparison of clinicopathological characteristics across different studies are presented 
in Table 4.1.1. Proportion of grade 1 and 2 tumours has been reported to be from the 
range of 77% to 92% (Pestalozzi et al. 2008;Sastre-Garau et al. 1996). In this series, 
proportion of grade 1 and 2 tumours is in agreement with others at 84.6% of the entire 
series and 88.2% of all evaluable tumours. Some authors do not advocate grading of 
lobular cancers as grading which is based on tubule formation, nuclear pleomorphism 
and mitosis (TPM) may not be accurate due to the fact that ILC generally lack tubule 
formation, and have low mitotic activity. Analyses by others have indicated an expected 
increase in disease recurrence with increasing tumour grade, but this is not conclusive 
and requires more comprehensive studies (Wachtel et al. 2010;Sinha et al. 2000). In this 
study, histological grading was able to retain its prognostic value after adjusting for 
confounding factors on multivariate analysis and we can consider grading all evaluable 
ILC tumours. Alternatively, a grading system that puts more emphasis on the degree of 
nuclear abnormality may be more suitable for grading ILC (Adams et al. 2009). The utility 








Table 4.1.1 Clinicopathological characteristics of ILC tumours from other studies.  
Data set 
Proportion 







































Garau et al. 
1996) 







77.0% 55.1% 69.5% 76.40% NA NA NA 
UK  
(Rakha et al. 
2009) 
92.0% 43.0% 69.5% 94.0% NA NA 
Tumour grade 
LN status 







NA NA NA 92.0% 75.0% 80.0% NA 
USA  
(Arpino et al. 
2004) 





LN: Lymph node 





4.2 Significance of immuno-marker expression 
 
Positive hormonal receptor status is one of the common characteristics of ILC. ER 
positive status has been reported in ILC, ranging from 76.4% to 93.6% (Sastre-Garau et 
al. 1996;Orvieto et al. 2008;Rakha et al. 2009;Pestalozzi et al. 2008;Korhonen et al. 
2004), the same high proportion of ER positivity was detected in our series at 91.6% 
(Table 4.1.1). Our proportion of PR positive cases (70.1%) was similar to those that 
others have reported ranging from 63% to 72% (Sastre-Garau et al. 1996;Arpino et al. 
2004;Korhonen et al. 2004).  
 
ER and PR status are important considerations when selecting patients for endocrine 
therapy and studies have constantly shown that patients who have positive hormonal 
receptors benefit from adjuvant tamoxifen treatment (Harvey et al. 1999;Elledge et al. 
2000;Bardou 2003). Nevertheless, we have not yet fully understood the influence of 
histologic type on response to endocrine therapy. An UK study on the outcome of 
hormonal therapy for ILC and matched IDC patients reported better survival outcome 
for ILC patients (Rakha et al. 2008). Another group’s investigation revealed ductal breast 
carcinoma to have achieved response to tamoxifen but the results for ILC are uncertain, 
due to small sample size (Jirstrom 2005). However, this study was unable to conclude 
the predictive value of ER and PR status as full treatment history and response of 






Low proliferative rate is expected of ILC. Proportion of tumours with high proliferative 
fraction for this series was 11.0% using a cut-off of at least 10% cells positive for Ki-67, a 
marker for proliferative activity. A study employing S-phase flow-cytomertry showed 
that only 13% of their ILC had high proliferation compared with 35% of IDC (Korhonen et 
al. 2004). Another primary lobular breast cancer study by (Orvieto et al. 2008) Orvieto et 
al. showed majority of ILC to have low proliferation (Ki-67<20%). Using their cut-off of 
20% positive cells, our proportion of high proliferative cases was reduced to 2.6%. 
 
Mammaglobin is a breast cancer specific protein that is overexpressed in a majority of 
breast cancers. It has been shown to be associated with ER positivity and CK 5 negativity 
(Sasaki et al. 2007) and other features that are associated with less aggressive tumour 
behaviour (Núñez-Villar et al. 2003). In our series, we detected 54.8% mammglobin 
positivity and its positive status was associated with tumours that are non-triple 
negative. 
 
4.3 E-cadherin and p120 catenin expression 
 
In this ILC series, 67.8% had complete negative expression for E-cadherin with the rest 
bearing aberrant expression of E-cadherin with variable intensity and pattern ranging 
from diminished to incomplete membrane expression. There are many mechanisms 
contributing to the loss of E-cadherin expression.  The most common abnormalities in 





chromosome 16q and promoter hypermethylation. Another well established mechanism 
contributing to the loss of E-cadherin expression is the repression of E-cadherin gene by 
transcription factors such as SNAIL, SLUG or ZEB (Aigner et al. 2007;Yook 2005;Peinado 
et al. 2007;Alves et al. 2007). Posttranslational inactivation of E-cadherin has also been 
implicated, where induction of metalloproteases and other proteases by cell matrix 
contact cause E-cadherin protein extracellular domain to be shed thereby facilitating 
dissemination of tumour cells. However, this mechanism does not necessarily explain 
the loss of E-cadherin protein expression (Symowicz et al. 2007;Maretzky et al. 2005). 
Accumulating evidence indicates the E-cadherin gene (CDH1) has tumour invasion 
suppression function (Berx et al. 1995;Huiping et al. 1999) and loss of E-cadherin 
expression is associated with less favourable tumour phenotype (Oka et al. 
1993;Gamallo et al. 1993). In this study, differences were identified between E-cadherin 
positive and negative ILC. E-cadherin positivity was more likely to be associated with 
tubulo-lobular variant, presence of LVI and absence of accompanying LCIS. However, 
there were no clinically significant differences in patients’ outcome between tumours 
that lack E-cadherin expression and tumours that express aberrant E-cadherin. A study 
on the aberrant expression of E-cadherin in ILC detected no association regarding 
clinicopathologic features, immunophenotype, or patients’ outcome other than 
association with histologic type of ILC (Rakha et al. 2010). The same study also reported 
the unexpected association of E-cadherin positive expression with the presence of LVI. 
Sarrio et al. (Sarrió et al. 2004) demonstrated that cytoplasmic localisation of p120 is the 





p120 relocalised to the junction after restoring of E-cadherin function.  Most of the 
tumours in this series reflected this observation where absence of p120 membrane 
localisation was strongly associated with complete loss of E-cadherin expression. 
 
Loss of both p120 catenin and E-cadherin expression can be explained by possible 
mutation in the p120 gene producing a non-functional p120 catenin (Ireton et al. 2002). 
This dysfunctional p120 catenin may impair the cadherin-catenin adhesion system, 
causing loss of stability in E-cadherin transmembrane protein. 
 
At the present, E-cadherin and p120 expression does not seem to have any prognostic 
value in this group of tumours. With the discovery and development of drugs that target 
epigenetic changes, it may be more meaningful to determine the expression of E-
cadherin and p120 as they may be important in selecting patients suitable for E-
cadherin specific epigenetic targeted therapy. 
 
4.4 Independent prognostic factors 
 
In our analysis, characteristics that had significant independent association with DFS and 
OS were tumour size, histologic grade and lymph node status. These characteristics are 
repeatedly proven to have prognostic significance in other studies. Arpino et al’s 
nationwide series of 4140 cases of ILC established higher lymph node status, larger 





recurrence and shortened survival (Arpino et al. 2004). A more recent large 
retrospective analysis of 350 pure ILC cases demonstrated positive lymph node 
metastasis, non-classic subtype and negative ER status to be adverse prognostic 
indicators in a multivariate analysis (Orvieto et al. 2008).  
 
On univariate analysis, it was observed that patients with accompanying LCIS performed 
better than patients without. The same outcome was observed comparing IDC and IDC 
presenting with adjacent DCIS (Wong et al. 2010). One postulate is that tumours with 
LCIS are detected earlier (Steenbergen et al. 2009), although the presence of 
accompanying LCIS was not proven to be an independent prognostic indicator in this 
study. 
 
4.5 ILC vs mixed ILC/IDC 
 
Many studies looking at the differentially expressed genes between ILC and IDC have 
found ILC to be distinct and have characteristic genomic profiles. Studies employing CGH 
have shown consistent gain in 1q and loss of 16q in ILC tumours (Yoder et al. 
2007;Buerger et al. 2000). ILC has been established as a distinct phenotypic entity 
supported by distinct molecular profile, but so far, ILC as a histologically distinct type did 
not have any difference in patient outcome when compared with IDC. This observation 





established for pure ILC and mixed ILC/IDC tumours. In fact, the factors that remained 
most important in prognosis were still traditional clinicopathological parameters.  
 
4.6 Pleomorphic variant 
 
The pleomorphic variant has been reported to be a more aggressive variant with high 
proportion of tumours overexpressing HER-2 and less proportion of tumours being 
hormone receptor positive (Frolik et al. 2001;Middleton et al. 2000). Here, this study 
agrees with other authors, reporting pleomorphic ILC having significantly higher grade 
(92.8% grade 2 and 3), and more triple negativity. There was a higher proportion of HER-
2 overexpressing tumours in the pleomorphic variant compared to non-pleomorphic, 
but contrary to other studies, this difference was not significantly associated. The 
pleomorphic variant was significantly associated with high proliferation and EGFR 
positivity in this series, reflecting the increase in aberrant genetic events acquired by 
tumours with this morphology. EGFR may be the pathway that drives the aggressive 
nature of this variant and this may present as another potential therapeutic option for 
patients with EGFR overexpressing tumours. On the overall outcome of pleomorphic ILC, 
other studies reported less favourable clinical course (Weidner and Semple 1992;Eusebi 
et al. 1992) while our analysis reported no association with worse outcome in terms of 
disease-free and overall survival compared to the other variants. Even when tumours 
were stratified into those with any pleomorphic component (mixed variant) versus 





confounded by differences in therapeutic treatment received which was not within the 
scope of this study.  
 
Although ILC tends to have low proliferation indicated by either Ki-67 
immunohistochemistry or S-phase flow-cytometry, there was a significant association of 
pleomorphic variant with higher proliferation (30.2% of pleomorphic tumours with high 
Ki-67 positive fraction versus 8.3% for non-pleomorphic tumours), once again 
emphasizing the aggressive nature of this variant of ILC. 
 
In our series of ILC, tumours classified as pleomorphic are more likely to be triple 
negative and being placed under these 2 categories confer more risk in terms of 
patient’s disease related outcome. Further characterisation into variants and by 
immuno-markers has valuable information for patient outcome and justifies a more 
cautious management. 
 
4.7 Basal phenotype 
 
Basal phenotype was associated with triple negativity and was shown to have more 
adverse clinical outcome. Basal cytokeratin expression by immunohistochemistry is 
frequently employed to define basal phenotype in breast tumours. There are reports of 
association of basal cytokeratin expression with significantly worse outcome (Nielsen 






Low representation of basal markers and low proliferative index are expected in ILC, this 
is in agreement with expression profiling studies where there is low expression levels of 
genes related with cell cycle and basal markers (Coradini et al. 2002). 
 
There are conflicting views on the existence of basal subset in ILC. A study of lobular 
carcinoma based on the absence of E-cadherin expression showed CK5/6 basal 
cytokeratin to be positive in 17% of their cases (Fadare et al. 2008). Natalya Khilko et al. 
study of pure lobular carcinoma diagnosed on histology found that all ILC in their series 
did not express basal cytokeratins, CK5/6, CK14 or CK17 (Khilko et al. 2010). This 
inconsistency could be due to the difference in quantifying the positive 
immunoexpression of basal markers. Fadare et al. used an arbitrary measure of any 
strong cytoplasmic/membrane staining as being positive while Khilko et al. used any 
unequivocally staining irrespective of intensity or distribution to be considered positive.  
 
Based on the tri-panel of CK14, EGFR and CK HMW, basal phenotype represented 98.6% 
of this ILC series. If only CK14 and EGFR were used, the proportion of basal phenotype 
was reduced to 17.1%. We conclude the existence of basal-like tumours in ILC. However, 
our basal phenotype based on CK14 or EGFR expression did not prove to have any worse 
outcome compared to non-basal tumours. Analysis based on individual basal marker 






In our analysis, 3.2% of this series were positive for EGFR, 15.4% positive for CK14 and 
CK HMW was positive in a large proportion of tumours at 86.4%. Based on previously 
defined tri-panel of CK14, EGFR and CK HMW, our proportion of basal tumour was 
markedly more than expected. CK HMW (34βE12) is a cocktail of cytokeratin 1, 5, 10 and 
14 and is commonly used to differentiate benign from malignant prostate glands. CK 
HMW is expressed in the basal cell layer of benign glands, and is absent in prostate 
adenocarcinoma (Leite et al. 2010;Brawer et al. 1985). Previous study on the expression 
of keratins in normal and malignant breast tissue shows the broad specificity of CK 
HMW (34βE12), with it staining luminal and basal epithelium in normal and benign 
specimens and all tumour cells in malignant specimens (Dairkee et al. 1988). In this 
series of lobular breast cancer, antibody cocktail CK HMW (34βE12) may not be the best 
antibody to detect basal phenotype. Future work may include investigating individual 
cytokeratin expression in ILC and to rule out any non-specific expression of 34βE12. 
 
4.8 Modified molecular classification 
 
Gene expression profiling studies have consistently observed the classification of breast 
tumours into molecular subtypes consisting of luminal, basal-like, HER-2 overexpressing 
and normal-like subtype (Sorlie et al. 2003;Sørlie et al. 2001;Jönsson et al. 2010). There 
is evidence of the existence of molecular subtypes in histologically lobular breast cancer 






Application of molecular classification using ER, PR and HER-2 allowed us to look at the 
distribution of molecular subtypes in this series, as well as the distribution of 
clinicopathological, immuno-marker status and outcome among the different molecular 
categories. Protein marker evaluation by immunohistochemistry is less expensive 
compared to molecular techniques such as DNA microarray and has already established 
practical predictive and prognostic clinical significance especially of ER, PR and HER-2. 
Stratification of lobular tumours by immuno-markers showed differences in patient 
survival according to the different subtypes. Molecular subtyping using ER, PR and HER-
2 immuno-markers as surrogates in this series revealed HER-2 overexpressing tumours 
to have the worst outcome compared to other subtype. The lowest 5 year overall 
survival occurs in HER-2 overexpressing group with cumulative survival of 62.5% in 
concordance with other studies that have also use surrogate markers for molecular 
subtype (Carey et al. 2006;Parise et al. 2009). In Praise et al.’s study on invasive breast 
cancer, histology type not specified, reported basal-like and HER-2 overexpressing 
subtypes as having the worst outcome (basal-76.2% and HER-2 overexpressed-75.9%) 
on 5 year overall survival (Parise et al. 2009).  
 
A Saudi Arabia subtyping study based on a panel of ER, PR, HER-2, EGFR and CK5/6 
immuno-markers reported luminal A subtype to be associated with ILC histotype (Al 
Tamimi et al. 2010). ILC are generally ER and PR positive and the same high proportion 
of luminal A and B in this series was expected. This may account for the improved 





positive receptors is an option to patients. The same study observed high Ki-67 
proliferative index in basal-like and HER-2 overexpressing subtype. 
 
Tumours positive for ER and PR may benefit from endocrine therapy, but with the same 
tumour overexpressing HER-2, the response may be different. Studies have shown that 
tumours that have overexpression of HER-2 and EGFR have reduced survival following 
adjuvant therapy of tamoxifen (Linderholm et al. 2009;Dihge et al. 2008) as a result of 
development of resistance to tamoxifen. Dependent on the expression profile of the 
tumours, different therapeutic strategies have to be employed to optimise treatment 
for individual patient. The immuno-profile of tumours has implications in decision for 




ILC is less common, with many studies on this histological type of tumour typically 
retrospective in nature. Existing clinical records may have inconsistency due to 
differences in documentation as these records span over a large number of years. 
Patient data may be incomplete due to loss of follow-up. Cases left out of the study due 
to incomplete information can potentially contribute to bias in outcome. In addition, 
there is no further information regarding pre- or post-surgical management that may be 






Immunohistochemistry is a single modality of investigation and it is not possible to 
extend its interpretation beyond prognostic and predictive value. Mutational profile of 
tumors and functional studies may contribute additional information but are not within 




This study summarised characteristics that can help to guide therapeutic options in 
patients who present with a lobular histologic type of breast tumour. It demonstrated 
the presence of tumour heterogeneity even in a distinct histologic type and recognised 
different prognostic groups in ILC. Basal-like tumours, triple negative ILC and the 
pleomorphic variant showed more aggressive characteristics but as individual categories, 
did not show any significant poorer outcome. Tumours that lacked hormonal receptors 
but overexpressed HER-2 have the worst outcome compared to other molecular 
subtypes. Tumour size, histologic grade and lymph node status were re-emphasized as 
independently associated with clinical outcome. E-cadherin abnormal expression was 
demonstrated in ILC but did not have any clinical significance. 
 
The clinicopathological profile of ILC in this study population has many similarities with 
other Asian and Western populations, with many of the same parameters being 
revealed to be prognostically important. It would imply that there are few differences in 





suggesting that there is no basis for risk or management stratification based on ethnicity. 
However, this postulate remains speculative as this study did not directly compare 
characteristics of the two populations. 
 
4.11 Future work 
 
It will be more complete to expand the clinicopathological parameters to include neo-
adjuvant or adjuvant therapy and its response in association with lobular histologic type. 
The benefit of neo-adjuvant chemotherapy for patients with ILC histologic type tumours 
is still uncertain. Many western studies have reported the lack of response to neo-
adjuvant chemotherapy in downstaging tumours especially where tumours that are 
hormone receptors positive and have low proliferation (Tubiana-Hulin 
2006;Purushotham et al. 2010). Further work to reveal the relationship with neo-
adjuvant chemotherapy and patient outcome can assist clinicians to weigh the value of 
these therapies with their possible side effects and consider if patients are being 
unnecessarily exposed to the toxicity of chemotherapy. 
 
It would be of great value to explore the mechanism of E-cadherin loss of expression in 
ILC and its association with patient outcome, and if these defective mechanisms may be 
targets for therapy. With the potential development of drugs which targets epigenetic 
changes, tumours with hypermethylation of the E-cadherin promoter region may be 
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